{"id":"W4417207111","doi":"10.1016/j.rpth.2025.103074","title":"HTRS2025.P2.54 Corticosteroid Experience With Fidanacogene Elaparvovec in Adults With Moderately Severe or Severe Hemophilia B: Results From the Phase 3 BENEGENE-2 Gene Therapy Trial","year":2025,"lang":"en","type":"article","venue":"Research and Practice in Thrombosis and Haemostasis","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Immune system; Corticosteroid; Genetic enhancement; Clinical trial; Virus; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007732368,0.0004182535,0.0006523444,0.00009053593,0.0002167645,0.0005524076,0.0002053034,0.0005269397,0.00381821],"category_scores_gemma":[0.0006445853,0.00008078008,0.0006654277,0.00017621,0.0003010604,0.0003173623,0.0001763514,0.001105399,0.0008016771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003342744,"about_ca_system_score_gemma":0.0004049512,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009588064,"about_ca_topic_score_gemma":0.001775023,"domain_scores_codex":[0.9997818,0.00009989428,0.00001440929,0.00002913323,0.00003178182,0.00004291036],"domain_scores_gemma":[0.9995918,0.00008756808,0.00006875618,0.00001995252,0.00002510401,0.0002068736],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4452728,0.01130747,0.01804089,0.001858056,0.002535227,0.001268839,0.0006548908,0.002471346,0.03529364,0.001510132,0.027915,0.4518717],"study_design_scores_gemma":[0.3892253,0.4822864,0.07727353,0.0006138597,0.001487694,0.002910272,0.0002010199,0.001105134,0.005710662,0.0009028444,0.03820791,0.00007536126],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9470451,0.03261739,0.001049789,0.002935647,0.0003268965,0.0007749214,0.002753914,0.00009334638,0.01240296],"genre_scores_gemma":[0.9827076,0.00753164,0.0007442623,0.002564288,0.0003593201,0.0005003729,0.002756412,0.00002027877,0.002815899],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00381821,"threshold_uncertainty_score":0.01277322,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1123467945773568,"score_gpt":0.4259008586316417,"score_spread":0.3135540640542849,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}